Please ensure Javascript is enabled for purposes of website accessibility

Elkridge-based Cel-Sci expands clinical trial sites

Cel-Sci Corp., of Vienna, Va., and Elkridge, said its Taiwanese clinical trial partner, Orient Europharma, has added additional sites in Taiwan in Cel-Sci’s Phase III head and neck cancer clinical trial for Multikine, the company’s flagship investigational immunotherapy.

The Multikine Phase III study is enrolling patients on three continents with advanced primary, not yet treated, head and neck cancer.

Cel-Sci is developing new immune system-based treatments for cancer and infectious diseases.

Multikine, Cel-Sci’s flagship investigational immunotherapy, is the first immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer.